Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
- PMID: 29221990
- DOI: 10.1016/j.jbior.2017.11.007
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients. Nevertheless, gemcitabine remains the standard first-line option for advanced-stage pancreatic cancer patients and, as resistance to the drug has attracted an increasing scientific interest, we deliberate on the main intracellular processes and proteins vital in acquired chemoresistance to gemcitabine. Lastly, our review examines various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs.
Keywords: Chemoresistance; Gemcitabine; Pancreatic cancer; Tumour microenvironment.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
-
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.Digestion. 2016;94(1):44-9. doi: 10.1159/000447739. Epub 2016 Jul 21. Digestion. 2016. PMID: 27438590 Review.
-
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.Crit Rev Oncog. 2019;24(2):199-212. doi: 10.1615/CritRevOncog.2019031641. Crit Rev Oncog. 2019. PMID: 31679214 Review.
-
Chemoresistance in Pancreatic Cancer.Int J Mol Sci. 2019 Sep 11;20(18):4504. doi: 10.3390/ijms20184504. Int J Mol Sci. 2019. PMID: 31514451 Free PMC article. Review.
-
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.Eur J Cancer. 2022 Oct;174:102-112. doi: 10.1016/j.ejca.2022.06.042. Epub 2022 Aug 18. Eur J Cancer. 2022. PMID: 35988408
Cited by
-
Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer.BMC Cancer. 2023 Nov 23;23(1):1137. doi: 10.1186/s12885-023-11645-0. BMC Cancer. 2023. PMID: 37996815 Free PMC article.
-
Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance.Cancers (Basel). 2022 Nov 24;14(23):5793. doi: 10.3390/cancers14235793. Cancers (Basel). 2022. PMID: 36497277 Free PMC article. Review.
-
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.Biomolecules. 2022 Jan 18;12(2):152. doi: 10.3390/biom12020152. Biomolecules. 2022. PMID: 35204653 Free PMC article. Review.
-
5-epi-Sinuleptolide from Soft Corals of the Genus Sinularia Exerts Cytotoxic Effects on Pancreatic Cancer Cell Lines via the Inhibition of JAK2/STAT3, AKT, and ERK Activity.Molecules. 2021 Nov 17;26(22):6932. doi: 10.3390/molecules26226932. Molecules. 2021. PMID: 34834023 Free PMC article.
-
Heteronemin promotes iron-dependent cell death in pancreatic cancer.Naunyn Schmiedebergs Arch Pharmacol. 2024 Mar;397(3):1865-1874. doi: 10.1007/s00210-023-02736-7. Epub 2023 Sep 29. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37773525
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical